January 31, 2024
1 min watch
Save
VIDEO: FDA approval of faricimab for RVO among highlights of 2023
In this expert perspective from Hawaiian Eye 2024, Sunir J. Garg, MD, FACS, FASRS, discusses the 2023 FDA approval of faricimab for the treatment of retinal vein occlusion.
“What we’ve seen with faricimab for RVOs is it is able to give us a very comparable anatomic response, comparable visual acuity response, with potentially better durability for our patients, which is always a big plus for them,” Garg, professor of ophthalmology at the retina service of Wills Eye Hospital at Thomas Jefferson University, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Garg reports consulting for Allergan, Apellis, Bausch + Lomb, Boehringer Ingelheim, Coherus, Johnson & Johnson Vision, Kanaph, Merck Manuals and New World Medical and serving as an independent research contractor for Adverum, Alexion, Annexon, American Academy of Ophthalmology, Apellis, Astellas, Avonelle-X, Boehringer Ingelheim, Genentech, Gyroscope, Iveric Bio, Jefferson, KCRN, Kodiak, Lineage Cell Therapeutics, MUST Network, NGM Biopharmaceuticals, Ocugen, OcuTerra, Opthea, Regeneron, Regenxbio and Roche.
Read more about